LBA29CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. (23rd October 2018) - Ko, A H; Cubillo, A; Kundranda, M; Zafar, S F; Meiri, E; Bendell, J; Alguel, H; Rivera Herrero, F; Ahn, E; Watkins, D; Pelzer, U; Charu, V; et al.